Solid Biosciences (SLDB) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Company overview and strategic focus

• Focuses on precision genetic medicine, primarily gene therapies, with three lead programs targeting Duchenne muscular dystrophy (DMD), Friedreich's ataxia (FA), and CPVT, plus additional pipeline assets and a proprietary capsid platform.

• Emphasizes innovation in gene therapy delivery, including capsids, promoters, dual plasmids, and manufacturing purity to improve investability and outcomes.

• Employs about 120 staff and collaborates with over 50 academic labs and small companies, aiming to expand partnerships further.

DMD program and regulatory progress

• Achieved alignment with the FDA on a registration study for DMD, seeking accelerated approval in the US, with a large safety database and over 36 patients dosed to date.

• No significant safety signals observed so far, including no drug-induced liver injury or myocarditis among the first 36 patients.

• Double-blind, placebo-controlled trial for DMD in boys aged 7–11 is set to begin dosing within 90 days, with the first patient already screened and a second lined up.

• Trial design incorporates FDA guidance, with time to rise as a primary endpoint and an 18-month assessment period to allow for meaningful clinical change.

• Method of steroid administration was optimized based on early trial learnings, leading to method-of-use patent filings.

Differentiation and innovation in gene therapy

• SGT-003 features a novel capsid with rapid, targeted muscle transduction and quick clearance from blood, reducing safety risks compared to earlier vectors.

• The construct includes additional proteins (nNOS, alpha-syntrophin, caveolin-4) for improved efficacy and cardiac protection.

• Manufacturing process achieves a high full-to-empty capsid ratio, enhancing expression and safety.

• Ease of use and reduced physician burden are expected to drive adoption, as current therapies require complex monitoring and additional drugs.